Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Company Overview - Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1] Product Development - The main drug in development is Seralutinib, which is an inhaled tyrosine kinase inhibitor targeting specific pathways related to PAH and PH-ILD [1]